Samy Ammari

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Roger Sun, Elaine Johanna Limkin, Maria Vakalopoulou et al. · The Lancet Oncology · 2018 · 1.2K citations

Tumor Immunology, Cancer Immunosurveillance, Oncologic Imaging +11

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Stéphane Champiat, Laurent Dercle, Samy Ammari et al. · Clinical Cancer Research · 2016 · 1.2K citations

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Christophe Massard, Stefan Michiels, Charles Ferté et al. · Cancer Discovery · 2017 · 747 citations

Mechanisms and therapeutic implications of hypermutation in gliomas

Mehdi Touat, Yvonne Y. Li, Adam N. Boynton et al. · Nature · 2020 · 661 citations · Full text

Neuro-oncology, Medicine, Therapeutic Implications +5

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

Mélodie Tazdait, Laura Mezquita, J. Lahmar et al. · European Journal of Cancer · 2017 · 337 citations

Oncology, Medicine, Recist 1.1 +6